HK1215266A1 - 緩激肽介導的病症的評估和治療 - Google Patents

緩激肽介導的病症的評估和治療

Info

Publication number
HK1215266A1
HK1215266A1 HK16103203.9A HK16103203A HK1215266A1 HK 1215266 A1 HK1215266 A1 HK 1215266A1 HK 16103203 A HK16103203 A HK 16103203A HK 1215266 A1 HK1215266 A1 HK 1215266A1
Authority
HK
Hong Kong
Prior art keywords
bradykinin
evaluation
treatment
mediated disorders
mediated
Prior art date
Application number
HK16103203.9A
Other languages
English (en)
Inventor
Daniel J Sexton
Ryan Faucette
Jon A Kenniston
Greg Conley
Andrew Nixon
Christopher Tenhoor
Burt Adelman
Yung Chyung
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of HK1215266A1 publication Critical patent/HK1215266A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
HK16103203.9A 2013-01-20 2016-03-18 緩激肽介導的病症的評估和治療 HK1215266A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361754607P 2013-01-20 2013-01-20
PCT/US2014/012107 WO2014113712A1 (en) 2013-01-20 2014-01-17 Evaluation and treatment of bradykinin-mediated disorders

Publications (1)

Publication Number Publication Date
HK1215266A1 true HK1215266A1 (zh) 2016-08-19

Family

ID=51210106

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103203.9A HK1215266A1 (zh) 2013-01-20 2016-03-18 緩激肽介導的病症的評估和治療

Country Status (21)

Country Link
US (2) US11156612B2 (zh)
EP (3) EP4234583A3 (zh)
JP (4) JP6444315B2 (zh)
KR (3) KR102523810B1 (zh)
CN (2) CN105073778B (zh)
AU (3) AU2014207420B2 (zh)
CA (2) CA2897336C (zh)
CY (1) CY1122164T1 (zh)
DK (1) DK2948479T3 (zh)
ES (1) ES2692408T3 (zh)
HK (1) HK1215266A1 (zh)
HR (1) HRP20181734T1 (zh)
HU (1) HUE041332T2 (zh)
IL (2) IL239428B (zh)
LT (1) LT2948479T (zh)
PL (1) PL2948479T3 (zh)
PT (1) PT2948479T (zh)
RS (1) RS57890B1 (zh)
SI (1) SI2948479T1 (zh)
TR (1) TR201815856T4 (zh)
WO (1) WO2014113712A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3459564T (pt) 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
WO2014152232A2 (en) 2013-03-15 2014-09-25 Dyax Corp. Anti-plasma kallikrein antibodies
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
KR102432826B1 (ko) 2013-10-21 2022-08-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
CN105874332B (zh) 2013-10-21 2019-11-12 戴埃克斯有限公司 自身免疫性疾病的诊断和治疗
KR20240033156A (ko) 2014-01-21 2024-03-12 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EP3286226A4 (en) * 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EP4354146A3 (en) * 2015-10-19 2024-06-05 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CO2018007216A2 (es) * 2015-12-15 2018-09-20 Dyax Corp Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido
CN109311847B (zh) 2016-05-31 2021-07-06 卡尔维斯塔制药有限公司 作为血浆激肽释放酶抑制剂的吡唑衍生物
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
AU2017325983B2 (en) * 2016-09-16 2023-12-07 Takeda Pharmaceutical Company Limited Protein biomarkers for diseases associated with the contact activation system
CN109716137B (zh) 2016-09-16 2023-07-21 武田药品工业株式会社 用于与接触活化系统相关的疾病的代谢产物生物标记
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
US11234939B2 (en) 2017-11-29 2022-02-01 Kalvista Pharmaceuticals Limited Dosage forms comprising a plasma kallikrein inhibitor
US20200407771A1 (en) * 2018-02-22 2020-12-31 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021202948A2 (en) * 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
WO2024003617A2 (en) * 2022-06-30 2024-01-04 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) * 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) * 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1993003748A1 (en) * 1991-08-13 1993-03-04 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
ES2528254T3 (es) 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
WO2004005934A2 (en) * 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2007079096A2 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
US20090075887A1 (en) 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
JP2009051259A (ja) 2007-08-23 2009-03-12 Yanmar Co Ltd 作業車両用独立型サスペンションの制御機構
JP5424331B2 (ja) * 2007-10-18 2014-02-26 国立大学法人 鹿児島大学 肝疾患診断用バイオマーカー
WO2009053050A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
WO2010065656A1 (en) 2008-12-02 2010-06-10 Joslin Diabetes Center Method for reducing blood pressure using inhibitors of plasma kallikrein
AU2013205086A1 (en) * 2009-01-06 2013-05-16 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
US8609866B2 (en) 2009-12-18 2013-12-17 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
PT3459564T (pt) * 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
EP2593121A2 (en) 2010-07-13 2013-05-22 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
JP5937612B2 (ja) 2010-12-02 2016-06-22 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 血液安定剤を含む採血用デバイス
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP3320922A1 (en) 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
SG11201505978PA (en) 2013-02-01 2015-08-28 Becton Dickinson Co Blood collection devices containing contact pathway inhibition additives
CN105874332B (zh) 2013-10-21 2019-11-12 戴埃克斯有限公司 自身免疫性疾病的诊断和治疗
KR102432826B1 (ko) 2013-10-21 2022-08-16 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR20240033156A (ko) 2014-01-21 2024-03-12 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
EP4354146A3 (en) 2015-10-19 2024-06-05 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen

Also Published As

Publication number Publication date
KR102203880B1 (ko) 2021-01-15
PL2948479T3 (pl) 2019-02-28
HRP20181734T1 (hr) 2018-12-28
JP2019055975A (ja) 2019-04-11
CN105073778B (zh) 2020-01-10
KR102381478B1 (ko) 2022-04-01
JP2021008483A (ja) 2021-01-28
JP7496380B2 (ja) 2024-06-06
EP2948479A4 (en) 2016-07-20
KR20150106006A (ko) 2015-09-18
IL273688A (en) 2020-05-31
JP2022084648A (ja) 2022-06-07
BR112015016231A2 (pt) 2017-07-11
JP6772237B2 (ja) 2020-10-21
CA2897336A1 (en) 2014-07-24
HUE041332T2 (hu) 2019-05-28
TR201815856T4 (tr) 2018-11-21
EP2948479B1 (en) 2018-08-01
JP2016511823A (ja) 2016-04-21
CA2897336C (en) 2023-10-17
IL239428B (en) 2020-04-30
KR102523810B1 (ko) 2023-04-21
EP3456744B1 (en) 2023-03-29
AU2014207420B2 (en) 2018-08-09
BR112015016231A8 (pt) 2019-10-29
EP2948479A1 (en) 2015-12-02
AU2020277178A1 (en) 2020-12-24
DK2948479T3 (en) 2018-11-26
PT2948479T (pt) 2018-11-14
SI2948479T1 (sl) 2019-01-31
AU2014207420A1 (en) 2015-07-02
JP6444315B2 (ja) 2018-12-26
US20150362493A1 (en) 2015-12-17
US11156612B2 (en) 2021-10-26
AU2020277178B2 (en) 2024-05-09
AU2018260845A1 (en) 2018-11-22
CN111044725A (zh) 2020-04-21
CA3209608A1 (en) 2014-07-24
CN111044725B (zh) 2024-03-29
EP3456744A1 (en) 2019-03-20
LT2948479T (lt) 2018-11-26
IL239428A0 (en) 2015-07-30
EP4234583A3 (en) 2024-01-24
RS57890B1 (sr) 2019-01-31
KR20220045992A (ko) 2022-04-13
US20220170936A1 (en) 2022-06-02
CY1122164T1 (el) 2020-07-31
ES2692408T3 (es) 2018-12-03
AU2018260845B2 (en) 2020-09-03
KR20210007044A (ko) 2021-01-19
WO2014113712A1 (en) 2014-07-24
CN105073778A (zh) 2015-11-18
EP4234583A2 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HRP20190528T1 (hr) PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
HK1216380A1 (zh) 附接裝置以及使用和製造的相關聯的方法
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
EP2983657A4 (en) TREATMENT OF GASTROINTESTINAL AND OTHER DISEASES
IL241191A0 (en) Local compositions and methods for treating local disorders
GB201320723D0 (en) Composition and methods of treatment
EP2999474A4 (en) THERAPEUTIC AND METHOD OF USE
HK1220352A1 (zh) 和神經變性疾病的治療
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1221166A1 (zh) 炎症性病症的治療
EP2968478A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA
HK1220453A1 (zh) 治療運動障礙和相關病症的方法
HK1222389A1 (zh) 肺病症和其他病症的治療